Viatris (VTRS) EBITDA Margin (2019 - 2026)
Viatris (VTRS) posted EBITDA Margin of 0.17% for Q2 2026, up 107.4% on a QoQ basis from 2.27% in Q1 2026, and down 634.0% year-over-year from 0.03% in Q2 2025.
Powered by 
Analysis
Viatris (VTRS) EBITDA Margin (2019 - 2026) Analysis & Trends
Viatris has reported EBITDA Margin for 8 years, with the latest figure at 0.17% in Q2 2026.
- On a quarterly basis, EBITDA Margin fell 634.0% year-over-year to 0.17% in Q2 2026; TTM through Jun 2026 was 0.59%, a 1785.0% increase from a year earlier, with the FY2025 full-year figure at 18.62%, down 1869.0% from the prior year.
- EBITDA Margin was 0.17% for Q2 2026 at Viatris, up from 2.27% in the prior quarter.
- The five-year high for EBITDA Margin was 16.88% in Q1 2022, with the low at 88.57% in Q1 2025.
- Average EBITDA Margin over 5 years is 1.44%, with a median of 5.16% recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: EBITDA Margin plunged 9413 bps in 2025, then jumped 8630 bps in 2026.
- Over 5 years, EBITDA Margin stood at 5.19% in 2022, then sank by 128 bps to 11.84% in 2023, then jumped by 57 bps to 5.1% in 2024, then retreated by 2 bps to 5.2% in 2025, then surged by 103 bps to 0.17% in 2026.
- The last three EBITDA Margin figures came in at 0.17% (Q2 2026), 2.27% (Q1 2026), and 5.2% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 25.95% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -134.08% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 15.21% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | 9.72% |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.17% |
| Mar 31, 2026 | -2.27% |
| Dec 31, 2025 | -5.20% |
| Sep 30, 2025 | 4.76% |
| Jun 30, 2025 | 6.50% |
| Mar 31, 2025 | -88.57% |
| Dec 31, 2024 | -5.10% |
| Sep 30, 2024 | 6.02% |
| Jun 30, 2024 | -6.32% |
| Mar 31, 2024 | 5.57% |
| Dec 31, 2023 | -11.84% |
| Sep 30, 2023 | 11.46% |
| Jun 30, 2023 | 9.42% |
| Mar 31, 2023 | 10.72% |
| Dec 31, 2022 | -5.19% |
| Sep 30, 2022 | 13.73% |
| Jun 30, 2022 | 13.33% |
| Mar 31, 2022 | 16.88% |
| Dec 31, 2021 | -1.79% |
| Sep 30, 2021 | 7.88% |